To investigate whether we could create a radiation-free conditioning regimen to induce permanent mixed and multilineage chimerism and donor-specific tolerance, we treated recipient mice with anti-T-cell antibodies, varying and fractionated doses of Treosulfan and fully MHC disparate bone marrow cells. Treosulfan is mainly used in the treatment of ovarian cancer. It is a structural analog of busulfan, but it does not induce severe hepatotoxicity or veno-occlusive disease at or above the maximum tolerated dose, lacks significant nonhematological toxicity and has limited organ toxicity. We report here the successful induction of permanent mixed multilineage chimerism and donor-specific tolerance as was proven by skin transplantation and IFN-c ELISPOT. In conclusion, because of its lower nonhematological toxicity, compared with other myeloablative regimens (eg irradiation or busulfan administration), Treosulfan could be a better candidate for conditioning to induce donor-specific allograft tolerance.
tolerance induction; myeloablation Rejection of transplanted organs is currently treated with immunosuppressive drugs. Although these drugs are very effective, their nonspecific suppression of the immune system may sometimes induce severe side effects like malignancies and a higher susceptibility to opportunistic infections in patients who are receiving organ transplantation. [1] [2] [3] However, the continuous risk of chronic rejections, which are difficult to treat, remains. Therefore, the induction of donor-specific tolerance is still a major goal in organ transplantation.
A promising solution is the establishment of mixed hematopoietic chimerism as it has several advantages over other tolerance-inducing methods. In mixed hematopoietic chimeras, tolerance to both host and donor is permanently established, leading to the absence of both graft-versus-host and host-versus-graft disease. 4 More importantly, neither long-term conditioning nor the life-long administration of immunosuppressive drugs is required. [5] [6] [7] Other methods (for example, in which costimulatory, cytokine pathways or NK cells are blocked), fail to inhibit completely the alloimmune response in many settings. 8, 9 Previously, we have developed a well-tolerated nonlethal myeloablative conditioning regimen to induce stable mixed and multilineage chimerism and donor-specific tolerance over a complete major histocompatibility complex (MHC) barrier. This model involves a single dose of anti-CD3 and anti-CD4 monoclonal antibodies, sublethal irradiation (6 Gy) and the transplantation of T-cell-depleted bone marrow cells (BMC). 4, 5, 10 The goal of the present study was to investigate whether the total body irradiation (TBI) in our conditioning model can be replaced by less toxic myeloablative drugs. Treosulfan (l-treitol 1,4-bismethanesulfonate, Ovastat s ) is an alkylating prodrug and a structural analog of busulfan. 11 It has mainly been used in the therapy of advanced ovarian cancer. [12] [13] [14] [15] However, it has been shown that Treosulfan has a broad spectrum of antitumor activity, for example, metastatic melanoma, 16 heterotransplanted human lung carcinomas, 14 human breast carcinomas 17 and human acute lymphoblastic leukemias. 17, 18 More importantly, only moderate side effects were seen and these were manageable and rapidly reversible. 19 Treosulfan lacks significant nonhematological toxicity and has a limited organ toxicity despite dose-escalation. 12 In the present study we show that Treosulfan is a very potent myeloablative drug that can replace TBI in our sublethal model. We demonstrate that triple doses of Treosulfan in combination with anti-T-cell monoclonal antibodies and bone marrow transplantation (BMT) also induce high levels of multilineage mixed chimerism and donor-specific tolerance over complete MHC barriers. Also, in combination with highly purified Sca-1 + Thy-1.2 lo Lin À cells, donor-type skin transplants are permanently accepted. These findings, together with the low nonhematological toxicity, make Treosulfan a very good candidate drug for myeloablative therapy in the case of donor-specific tolerance induction.
Materials and methods

Animals
Male C57BL/10 (B10, H-2 b ), B10.D2 (H-2   d ) and B10.BR (H-2 k ) mice (8-14-week-old) were used as recipients, donors and third parties, respectively. Recipient C57BL/10 mice were obtained from Harlan (Horst, The Netherlands). The other animals were bred in the Central Animal Laboratory. All mice were maintained at the animal facility of the Central Animal Laboratory of the National Institute of Public Health and the Environment, under specific pathogen-free conditions.
Monoclonal antibodies
Anti-CD3, a hamster IgG monoclonal antibody (mAb) produced from hybridoma 145-2C11, was generously provided by Dr JA Bluestone (University of Chicago, Chicago, IL, USA) and is reactive against the CD3-e chain of the murine T-cell receptor. 20 The mAb was purified on a protein A-sepharose column. The rat IgG2b mAb GK1.5, directed against the CD4 antigen (anti-CD4, American Type Culture Collection, Rockville MD, USA), was purified using high-performance liquid chromatography (HPLC, Perkin-Elmer Series 410) with an ABX ionexchange column, especially suited for antibody binding. Eluted mAbs were dialyzed against PBS, sterilized through a 0.22 mm filter (Satorius AG, Goettingen, Germany), and frozen at -201C until used. Protein concentration was determined by absorbance at 280 nm. The purity of the mAbs was confirmed by SDS-PAGE.
Biotinylated anti-Sca-1 (clone D7) mAb and anti-I-A d (clone 39-10-8), FITC-labeled anti-Thy1.2 (CD90.2; clone 53-2.1) and anti-H-2D d (clone 34-2-12), and PE-labeled anti-CD8 (clone 53-6.7), anti-CD4 (clone H129.19), antiCD11b (clone M1/70), anti-CD45R/B220 (clone RA3-6B2), anti-GR-1 (clone RB6-8C5) and anti-H-2K b (clone AF6-88.5) were purchased from Pharmingen (San Diego, CA, USA). Microbead-labeled anti-B220 (clone RA3-6B2), anti-TER119 (clone Ter-119), anti-CD11b (clone M1/ 70.15.11.5), anti-CD8 (clone 53-6-7) and streptavidin microbeads were obtained from Miltenyi Biotec (Bergisch Gladbach, Germany).
Preparation of bone marrow suspensions
Using sterile procedures, BMC were obtained by flushing femoral and tibial bones from donor mice with Iscove's modified Dulbecco's medium (IMDM; Life Technologies, Paisley, Scotland) supplemented with 10% heat inactivated fetal calf serum (FCS; Hyclone, UT, USA), 2-mercaptoethanol (5 Â 10 -5 m), penicillin (100 IU/ml) and streptomycin (100 mg/ml). After lysis of erythrocytes with an ammonium chloride buffer, BMC were depleted of T cells by treatment with anti-Thy-1.2 mAb (F7D5; Serotec, Wiesbaden, Germany) and complement (low-tox M rabbit complement, Cedarlane, Hornby, ONT, Canada). 
Isolation of hematopoietic stem cells (HSC)
Lin
À cells or unseparated BMC to allow limiting dilution analysis of the precursor cells forming hematopoietic clones under the stromal layers as previously described. 21 Briefly, to assay a particular cell suspension, we used 12 dilution steps differing by a factor of 2, with 15 wells per dilution. The cells were cultured at 331C in 10% CO 2 and were fed weekly by changing half of the medium. Between 7 and 49 days after overlay, all wells were inspected at weekly intervals and scored positive if at least one phase-dark hematopoietic clone (cobblestone area, at least five cells) was observed. The CAFC frequencies were calculated using Poisson statistics.
Preparation of chimeras
To induce long-term stable multilineage mixed chimerism, recipient mice were treated on days À3, À2 and -1 with Treosulfan (Ovastat s , a generous gift from Medac, Hamburg, Germany). Treosulfan was dissolved in water and subsequently kept at 35-371C until caudal vein injection. On day 0, a single dose of 400 mg anti-CD3 was given intraperitoneally (i.p.). Subsequently, recipient animals were reconstituted on day 0 with either 15 Â 10 6 donor-BMC or 20 Â 10 3 Sca-1 + Thy1.2 lo Lin À cells. All BMC were injected via the caudal vein injection in 0.2 ml of saline, containing 5% heat inactivated autologous serum. On day -1, recipient mice were also given 500 mg of GK1.5 i.p., a depleting anti-CD4 mAb, in order to reduce the contribution of CD4 + T cells to the 'cytokine release syndrome', which is associated with anti-CD3 treatment. 22 
Flow cytometry analysis
Donor cell engraftment was determined by flow cytometry using a FACS Calibur (Becton Dickinson, Mountain View, CA, USA) on days 20, 40, 80 and 100 after BMT. In addition, on the day the mice were killed, donor chimerism was analyzed (4day 120 post-BMT). All procedures were performed in FACS buffer, containing 1% bovine serum albumin and 5 mm EDTA. Fluorescence data were collected by using logarithmic amplification on 10 000 viable cells as determined by forward light scatter intensity. To quantify chimerism, cells were stained with anti-H-2D 
Skin transplantation
After completing the conditioning regimen, tail skin transplantation was performed. Each recipient was given a control syngeneic (B10), a donor (B10.D2) and a thirdparty (B10.BR) skin graft 6 weeks after BMC transfusion. The grafts were inspected three times a week for 100 days and were considered to be rejected when no viable donor skin was detectable. 
Statistical analysis
Data were analyzed for statistical significance (Instat, Version 3.01, Graphpad, San Diego, CA, USA) using the Tukey-Kramer comparison test. A P-value of o0.05 was considered to be significant.
Results
Mixed hematopoietic chimerism can be established using Treosulfan as a myeloablative drug
To investigate whether Treosulfan could replace TBI as a myeloablative agent in our sublethal BMT model, it was given at various doses to recipient mice on days À3, À2 and À1 before the transplantation of fully MHC disparate B10.D2 T-cell-depleted BMC and a single dose of anti-CD3 and anti-CD4. There were neither signs of toxicity nor early deaths because of treatment with Treosulfan. At several time points after transplantation, donor chimerism was measured. The number of mice with stable mixed multilineage chimerism increased with higher Treosulfan concentrations. After administration of triple doses of 500, 1000, 1500 and 2000 mg/kg, the incidence of chimerism was, respectively, 0, 37.5, 100 and 100%. In addition, an increase in the dose of Treosulfan also led to an increase in the percentage of donor-type cells in the recipient mice. Mice that were given triple doses of 1500 mg/kg (total dose 4500 mg/kg) and 2000 mg/kg (total dose 6000 mg/kg) were, respectively, 54 and 84% chimeric for donor cells on day 100 after BMT ( Figure 1a , Table 1 ). In addition, chimerism was mixed and multilineage ( Figure 1b) . When the dose was further decreased to 3 Â 1000 mg/kg (total dose 3000 mg/kg), 11.3% donor cells were present in the peripheral blood of the chimeras on day 100 after BMT.
Mixed multilineage chimeric mice are donor-specific tolerant in vivo and in vitro To investigate whether stable mixed multilineage chimeric mice were also donor-specific tolerant, tail skin transplantations were performed. Recipient mice were given a recipient (B10)-, donor (B10.D2) and third-party-type (B10.BR) skin transplant. All chimeric mice permanently accepted donor-type skin grafts (472 days) and rapidly rejected third-party skin grafts (median survival time (MST) 21 days). Mice that received the conditioning regimen but did not become chimeric (non chimeras) rejected donor-type skin grafts within 19 days (MST 17.5 days). In addition, recipient-type (B10) skin grafts were also permanently accepted (Figure 2a) .
We also measured the reactivity against donor and thirdparty cells in an IFN-g ELISPOT assay. Spleen cells from chimeric mice produced less spots when incubated with donor-type (B10.D2) cells, compared to non chimeras and control untreated recipient-type (B10) mice (Figure 2b) . In contrast, when incubated with third-party (B10.BR) spleen cells, no difference in the frequency of IFN-g-producing cells was found compared to control nonchimeras and control untreated recipient-type (B10) mice (83, 139 and 167 spots per 10 6 cells, respectively). In conclusion, these data show that mice conditioned using anti-CD3 and anti-CD4 mAbs, Treosulfan and T-cell-depleted donor-BMC become stable mixed multilineage chimeric and donorspecific tolerant over complete MHC barriers.
T-cell-depleted donor bone marrow transfusion can be replaced by hematopoietic stem cell transplantation Figure 3 and Table 3 ). These mixed chimeras were also donor-specific tolerant, because donor-type skin grafts were permanently accepted by all chimeric mice, whereas third-party skin grafts were rejected within 19 days (MST 18.5 days). Moreover, recipient-type skin grafts were permanently accepted (490 days; Figure 4a ). Donor-specific tolerance of chimeric mice treated with 2000 mg/kg Treosulfan was confirmed in vitro by IFN-g ELISPOT (Figure 4b ). The frequency of cells from chimeras that are producing IFN-g upon incubation with irradiated donor-type cells is decreased compared with control non chimeras and control untreated recipient-type (B10) mice (69, 600 and 300 cells per 10 6 respectively). In conclusion, the transplantation of 20 Â 10 sulfan and anti-T cell mAbs are able to induce multilineage mixed chimerism and donor-specific tolerance over a complete MHC barrier.
Discussion
Previously, we established a murine model for the induction of donor-specific transplantation tolerance, which involves a single dose of anti-T cell mAb, low-dose TBI (6 Gy) and the transplantation of T-cell-depleted donor BMC. This conditioning regimen results in mixed multilineage chimerism and donor-specific tolerance. In order to create a radiation-free conditioning protocol, we have, in the current report, replaced TBI with Treosulfan, which was well-tolerated. We clearly show that mice treated with a triple dose of 1500 mg/kg Treosulfan and a single dose of completely MHC-mismatched BMC and anti-T-cell mAbs become reproducibly multilineage mixed chimeric and donorspecific tolerant both as assessed in vitro and in vivo.
Furthermore, we also demonstrated in the current report that BMC can be replaced by purified HSC. All chimeras were still immunocompetent since third-party (B10.BR) skin grafts were rejected. However, the frequency of cells from chimeras that produced IFN-g upon incubation with third-party (B10.BR) spleen cells is decreased compared with control recipient (B10) mice. This might be explained by our finding that donor cells (B10.D2) themselves show a decreased anti-third-party (B10.BR) response (data not shown). In chimeras, cells from both recipient and donor coexist, resulting in a decreased anti-third-party response.
Previously, we have shown in our model that 1 Â 10 6 fetal liver or BM c-kit + cells induced donor-specific tolerance. 23 However, this c-kit + cell population contains progenitor cells in addition to HSC. 24 In order to decrease the number of cells to be infused, we further isolated Sca-1 + Thy-1.2 lo Lin À cells. In our hands this cell population is B500-fold enriched for HSC activity and contains both STRA and LTRA cells. In this study we have shown that 20 Â 10 
Lin
À cells were able to reconstitute mice. 27, 28 This seems to be in sharp contrast to the number of cells we are injecting, although, the recipients used in those studies were lethally irradiated 27, 28 or donor and recipient were haploidentical. 27 It has been shown that an MHC restriction exists between HSC and stromal cells in vivo 29 and that stromal cells are functionally damaged by 8 Gy irradiation. 29 This explains why the engraftment of BMC haploidentical to the recipient or into lethally irradiated mice requires a lower number of cells to be transplanted.
Treosulfan is indicated for oral or i.v. treatment of patients with ovarian carcinoma in several European countries, 12, 30 but has also been shown to be effective in the treatment of several malignancies. 13, 14, [16] [17] [18] In addition, efficient stem cell toxicity against committed and primitive stem cells was evident when fractionated and escalated doses of Treosulfan were administered before BMT. [31] [32] [33] Treosulfan is a prodrug of a bifunctional alkylating cytostatic. Its mechanism of action is based on a nonenzymatic pH-and temperature-dependent formation of mono-and diepoxybutane derivatives. 11, 12, 30 These derivatives are responsible for DNA alkylation and DNA interstrand cross-linking followed by DNA fragmentation and cell death. 12 Previously, a number of other radiation-free murine models, in which mixed multilineage chimerism and donorspecific tolerance is induced, have been described, for example, in which the conditioning regimen contains busulfan, 34 dimethyl myleran 35 or a combination of busulfan and cyclophosphamide. 36 In addition, we have shown that TBI in our model can be replaced successfully by a single low dose of dimethyl myleran in combination Treosulfan induces tolerance across MHC barriers M van Pel et al with cyclophosphamide. 37 Our current results confirm that TBI in our sublethal model can be replaced by other myeloablative regimens. However, in contrast to busulfan, Treosulfan does not induce severe hepatotoxicity or venoocclusive disease in patients treated at or above the maximum tolerated dose. 12 Furthermore, Treosulfan lacks significant nonhematological toxicity and has a limited organ toxicity, which was currently demonstrated in clinical protocols using dose-escalated Treosulfan in combination with autologous and allogeneic hematopoietic stem cell transplantation. 12, 38, 39 When BM or HSC transplantation is used to achieve donor-specific tolerance, the toxicity of the conditioning regimen has to be evaluated and compared to the toxicity of conventional immunosuppressive therapies. Tolerance induction by mixed chimerism has the potential to solve both the complications of nonspecific immuno- suppression and the problems of chronic allograft rejection, and may therefore be preferable to chronic immunosuppressive therapies. In conclusion, Treosulfan is a very interesting candidate drug not only in the treatment of ovarian cancer but also for more experimental clinical therapies using HSC transplantation, including hematological malignancies, severe autoimmune diseases or for the long-term induction of donor-specific tolerance in organ transplantation.
